Sedation: Clinical Trials

13 trials for Sedation, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 completed. 13 Phase 2, 3 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 213Completed 13
Phase 33Completed 3
Phase 11Completed 1

Follow Sedation: new trials by email Literature Review of Sedation trials Research Report on Sedation

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Esketamine Combined With Dexmedetomidine Sedation in Head MRI Examination of Children With Autism Spectrum Disorder
low dos dexmedetomidine, high dos dexmedetomidine, dexmedetomidine and esketamine - Autism Spectrum Disorder, Dexmedetomidine
Phase 2CompletedMaternal and Child Health Hospital of Hubei Province3002022-12-012024-10-09
A Study Evaluating the Efficacy and Safety of HSK3486 for Sedation
HSK3486 0.1-0.2 /0.3 mg / kg group, Propofol 0.5-1.0/1.5 mg/kg group - Sedation
Phase 2CompletedSichuan Haisco Pharmaceutical Group Co., Ltd392019-11-222022-05-27
Propofol vs. Midazolam With Propofol for Sedative Endoscopy in Patients With Previous Paradoxical Reaction to Midazolam
Propofol, Midazolam - Sedation, Endoscopy
Phase 2CompletedDongGuk University302018-10-192020-12-29
Pharmacokinetics and Pharmacodynamics of Oral Transmucosal Dexmedetomidine.
OTM Dexmedetomidine 1µg/ kg., OTM Dexmedetomidine 0.75µg/ kg., OTM Dexmedetomidine 0.5µg/ kg. - Sedation
Phase 2 / Phase 3CompletedAssiut University362017-04-052019-08-01
Safety And Efficacy Of Dexmedetomidine Sedation In Intubated Mechanically Ventilated Infants With Respiratory Failure
Dexmedetomidine 0.35µg/kg /h, Dexmedetomidine 0.5µg/kg /h - Sedation
Phase 2 / Phase 3CompletedAssiut University402016-12-012018-07-03
A Study of Remimazolam Tosilate in Patients Undergoing Diagnostic Upper GI Endoscopy
Remimazolam Tosilate, Propofol - Sedation
Phase 2CompletedJiangsu HengRui Medicine Co., Ltd.1532016-11-012017-09-08
Phase II Pharmacokinetic and Pharmacodynamic Study of DEX in Subjects Aged 12 Months Through <24 Months
Dexmedetomidine - Sedation, Pain
Phase 2CompletedHospira, now a wholly owned subsidiary of Pfizer52011-06-012015-07-24
Safety, Efficacy and Pharmacokinetic Study of Dexmedetomidine in Pediatrics Ages ≥28 Weeks to ≤44 Weeks Gestational Age
Midazolam, Fentanyl/Morphine, Dexmedetomidine - Sedation
Phase 2 / Phase 3CompletedHospira, now a wholly owned subsidiary of Pfizer362010-07-012015-08-13
Multiple Dose Safety and Efficacy Study Evaluating CNS 7056 Versus Midazolam in Patients Undergoing Colonoscopy
A. CNS 7056, B. CNS 7056, C. CNS 7056 - Sedation
Phase 2CompletedPaion UK Ltd.1622010-05-012019-01-08
A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction Procedure
Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03), Placebo NanoTab™ - Sedation, Anxiety
Phase 2CompletedTalphera, Inc402009-06-012014-06-25
Dexmedetomidine Cardiovascular Safety in Pediatric Burn Patients
Dexmedetomidine - Burns, Sedation
Phase 2CompletedMassachusetts General Hospital82007-07-162017-07-17
Acute Neurological ICU Sedation Trial (ANIST)
Fentanyl/Dexmedetomidine, Fentanyl/Propofol, Fentanyl - Sedation
Phase 2CompletedJohns Hopkins University352005-05-012019-05-16
Clonidine-Remifentanil. Effect of the Combination on Acute Pain and Respiration in Healthy Volunteers
Remifentanil+clonidine - Acute Pain, Respiration
Phase 1 / Phase 2CompletedOslo University Hospital122005-02-012011-07-06

Narrower conditions

Pain (2)  ·  Acute Pain (1)  ·  Anxiety Disorders (1)  ·  Autism Spectrum Disorder (1)  ·  Burns (1)  ·  Respiratory Aspiration (1)

Broader conditions

Neurologic Manifestations (3)  ·  Pathological Conditions, Signs and Symptoms (3)  ·  Signs and Symptoms (3)  ·  Mental Disorders (2)  ·  Child Development Disorders, Pervasive (1)  ·  Neurodevelopmental Disorders (1)  ·  Pain (1)  ·  Pathologic Processes (1)  ·  Respiration Disorders (1)  ·  Respiratory Tract Diseases (1)  ·  Wounds and Injuries (1)

Interventions

Dexmedetomidine (7)  ·  Propofol (3)  ·  Fentanyl (2)  ·  Midazolam (2)  ·  Clonidine (1)  ·  Esketamine (1)  ·  Morphine (1)  ·  Remifentanil (1)  ·  remimazolam (1)

Sponsors

Assiut University (2)  ·  Hospira, now a wholly owned subsidiary of Pfizer (2)  ·  DongGuk University (1)  ·  Jiangsu HengRui Medicine Co., Ltd. (1)  ·  Johns Hopkins University (1)  ·  Massachusetts General Hospital (1)  ·  Maternal and Child Health Hospital of Hubei Province (1)  ·  Oslo University Hospital (1)  ·  Paion UK Ltd. (1)  ·  Sichuan Haisco Pharmaceutical Group Co., Ltd (1)  ·  Talphera, Inc (1)

Countries

United States (6)  ·  China (3)  ·  Egypt (2)  ·  Guatemala (1)  ·  Norway (1)  ·  South Korea (1)

Top investigators

Constantinos Chrysostomou, MD (1)  ·  Erik S Shank, MD (1)  ·  Hala S Abdel-Ghaffar, MD (1)  ·  Jon B Bergmann, Ass. Prof. (1)  ·  Linli Yue, MD (1)  ·  Marek Mirski, MD, PhD (1)  ·  Pamela Palmer, M.D., PhD (1)  ·  Saher A Mohamed, MD (1)

Results publications

PMID 15460178, PMID 21926576, PMID 24238862, PMID 24893689, PMID 26363333, PMID 32889844, PMID 34924506, PMID 39455495